13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001425738
Total reported value
$1.5B
$1.5B
63 檔
34.1%
According to the latest 13F quarterly dataset, Redmile Group, LLC managed an equity portfolio of $1.5B at the end of Q2 2024, spanning 63 distinct U.S. exchange-listed positions.
In Q2 2024, Redmile Group, LLC adopted a defensive or profit-taking posture, trimming 21 positions and completely liquidating 14 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 11.34% | +4.25% | -32.30% | |
| 2 | AM6 | Amicus Therapeutics Inc | Stock-Other | 6.35% | — | -20.08% | |
| 3 | NRIX | Nurix Therapeutics Inc | Stock-Other | 5.58% | -1.30% | -1.32% | |
| 4 | STOK | Stoke Therapeutics Inc | Stock-Other | 3.86% | -0.31% | -6.94% | |
| 5 | IMNM | Immunome Inc | Stock-Other | 3.58% | -1.06% | — | |
| 6 | RGNX | Regenxbio Inc | Stock-Other | 3.23% | +1.09% | +0.40% | |
| 7 | LIVN | LivaNova PLC | Stock-Other | 3.08% | +0.05% | -10.43% | |
| 8 | REPL | Replimune Group Inc | Stock-Other | 3.03% | — | +49.12% | |
| 9 | ✓ | Adc Therapeutics SA | Stock-Other | 2.92% | -3.01% | — | |
| 10 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.85% | — | -8.93% | |
| 11 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.75% | -13.59% | -15.06% | |
| 12 | ZYME | Zymeworks Inc | Stock-Other | 2.68% | +0.04% | -6.29% | |
| 13 | FATE | Fate Therapeutics Inc | Stock-Other | 2.61% | +1.31% | — | |
| 14 | COGT | Cogent Biosciences Inc | Stock-Other | 2.45% | -0.44% | +21.13% | |
| 15 | BEAM | Beam Therapeutics Inc | Stock-Other | 2.41% | +0.73% | -9.39% | |
| 16 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 2.31% | +0.84% | -0.66% | |
| 17 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.29% | — | -13.14% | |
| 18 | BHVN | Biohaven Ltd. | Stock-Other | 2.28% | — | -6.50% | |
| 19 | NGNE | Neurogene Inc | Stock-Other | 2.23% | +1.03% | +8.38% | |
| 20 | PLRX | Pliant Therapeutics Inc | Stock-Other | 2.09% | — | +3.63% | |
| 21 | CTLTEUR | Catalent Inc | Stock-Other | 2.02% | — | -5.83% | |
| 22 | ANNX | Annexon Inc | Stock-Other | 1.90% | -0.79% | +16.80% | |
| 23 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.82% | — | -30.43% | |
| 24 | IDYA | Ideaya Biosciences Inc | Stock-Other | 1.61% | +0.45% | -17.68% | |
| 25 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.61% | +0.53% | -19.83% | |
| 26 | ABSI | Absci CORP | Stock-Other | 1.54% | +3.60% | — | |
| 27 | KROS | Keros Therapeutics Inc | Stock-Other | 1.53% | — | — | |
| 28 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 1.47% | -0.03% | -6.70% | |
| 29 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.36% | — | -14.90% | |
| 30 | STTK | Shattuck Labs Inc | Stock-Other | 1.31% | +0.85% | — | |
| 31 | 1K0 | Igm Biosciences Inc | Stock-Other | 1.28% | — | — | |
| 32 | IMVT | Immunovant Inc | Stock-Other | 1.15% | — | -25.73% | |
| 33 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.07% | — | +34.85% | |
| 34 | AUGX | Augmedix Inc | Stock-Other | 0.87% | — | — | |
| 35 | ETNBGBP | 89bio Inc | Stock-Other | 0.85% | — | -22.91% | |
| 36 | ARDX | Ardelyx Inc | Stock-Other | 0.84% | -0.07% | -14.27% | |
| 37 | SYK | Stryker CORP | Stock-Healthcare | 0.81% | — | -8.70% | |
| 38 | PRME | Prime Medicine Inc | Stock-Other | 0.64% | -0.03% | — | |
| 39 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.62% | — | -16.50% | |
| 40 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.59% | +0.12% | +86.31% | |
| 41 | NUVB | Nuvation Bio Inc | Stock-Other | 0.54% | +0.26% | — | |
| 42 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.48% | — | -56.30% | |
| 43 | ACIU | AC Immune SA | Stock-Other | 0.44% | — | -9.93% | |
| 44 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.43% | — | -8.79% | |
| 45 | RPTX | Repare Therapeutics Inc | Stock-Other | 0.39% | — | -3.66% | |
| 46 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.37% | — | -30.78% | |
| 47 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.30% | — | — | |
| 48 | BOLD | Boundless Bio Inc | Stock-Other | 0.24% | — | -7.13% | |
| 49 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.23% | +0.20% | — | |
| 50 | STXS | Stereotaxis Inc | Stock-Other | 0.23% | — | -36.28% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NRIX | Nurix Therapeutics Inc | +3.2% | -1.32% | Trim |
| 2 | REPL | Replimune Group Inc | +1.9% | +49.12% | Add |
| 3 | KRYS | Krystal Biotech Inc | +1.5% | -32.30% | Trim |
| 4 | COGT | Cogent Biosciences Inc | +1.5% | +21.13% | Add |
| 5 | LIVN | LivaNova PLC | +1% | -10.43% | Trim |
| 6 | AM6 | Amicus Therapeutics Inc | +0.6% | -20.08% | Trim |
| 7 | AKRO | Akero Therapeutics Inc | +0.6% | -13.14% | Trim |
| 8 | ZYME | Zymeworks Inc | +0.5% | -6.29% | Trim |
| 9 | NGNE | Neurogene Inc | +0.5% | +8.38% | Add |
| 10 | ANNX | Annexon Inc | +0.5% | +16.80% | Add |
| 11 | BSX | Boston Scientific CORP | +0.4% | -30.43% | Trim |
| 12 | ✓ | Adc Therapeutics SA | +0.4% | — | Unchanged |
| 13 | PLRX | Pliant Therapeutics Inc | +0.4% | +3.63% | Add |
| 14 | KYMR | Kymera Therapeutics Inc | +0.3% | -8.93% | Trim |
| 15 | CLDX | Celldex Therapeutics Inc | +0.2% | -19.83% | Trim |
| 16 | KROS | Keros Therapeutics Inc | +0.2% | — | Unchanged |
| 17 | 1K0 | Igm Biosciences Inc | +0.2% | — | Unchanged |
| 18 | BEAM | Beam Therapeutics Inc | +0.1% | -9.39% | Trim |
| 19 | IDYA | Ideaya Biosciences Inc | +0.1% | -17.68% | Trim |
| 20 | IMVT | Immunovant Inc | — | -25.73% | Trim |
| 21 | BHVN | Biohaven Ltd. | -0.1% | -6.50% | Trim |
| 22 | FDMT | 4d Molecular Therapeutics In | -0.1% | -14.90% | Trim |
| 23 | ETNBGBP | 89bio Inc | -0.1% | -22.91% | Trim |
| 24 | VTYXUSD | Ventyx Biosciences Inc | -0.1% | — | Unchanged |
| 25 | ABSI | Absci CORP | -0.2% | — | Unchanged |
| 26 | TRDA | Entrada Therapeutics Inc | -0.2% | -56.30% | Trim |
| 27 | RGNX | Regenxbio Inc | -0.3% | +0.40% | Add |
| 28 | ALXO | Alx Oncology Holdings Inc | -0.3% | -6.70% | Trim |
| 29 | APLSUSD | Apellis Pharmaceuticals Inc | -0.3% | EXIT | Sold out |
| 30 | BOLD | Boundless Bio Inc | -0.3% | -7.13% | Trim |
| 31 | ✓ | Verve Therapeutics Inc | -0.4% | -8.79% | Trim |
| 32 | 2JQ | Gritstone Bio Inc | -0.4% | -11.25% | Trim |
| 33 | PEN | Penumbra Inc | -0.4% | EXIT | Sold out |
| 34 | ELAN | Elanco Animal Health Inc | -0.4% | EXIT | Sold out |
| 35 | DGX | Quest Diagnostics Inc | -0.4% | EXIT | Sold out |
| 36 | MCK | Mckesson CORP | -0.4% | EXIT | Sold out |
| 37 | PGNY | Progyny Inc | -0.5% | EXIT | Sold out |
| 38 | ICLR | ICON Public Limited Company | -0.5% | EXIT | Sold out |
| 39 | STTK | Shattuck Labs Inc | -0.5% | — | Unchanged |
| 40 | ELV | Elevance Health Inc | -0.6% | EXIT | Sold out |
| 41 | HCA | Hca Healthcare Inc | -0.6% | EXIT | Sold out |
| 42 | EVH | Evolent Health Inc - A | -0.8% | EXIT | Sold out |
| 43 | IMNM | Immunome Inc | -0.9% | — | Unchanged |
| 44 | CI | THE Cigna Group | -0.9% | EXIT | Sold out |
| 45 | FATE | Fate Therapeutics Inc | -0.9% | — | Unchanged |
| 46 | ALGN | Align Technology Inc | -1.1% | EXIT | Sold out |
| 47 | ABT | Abbott Laboratories | -1.1% | EXIT | Sold out |
| 48 | SRRK | Scholar Rock Holding CORP | -1.4% | -15.06% | Trim |
| 49 | AUGX | Augmedix Inc | -1.6% | — | Unchanged |
| 50 | DCPHEUR | Deciphera Pharmaceuticals In | -3.1% | EXIT | Sold out |
According to official SEC Form 13F filings, Redmile Group, LLC reported a total U.S. public equity portfolio value of $1.5B across 63 disclosed positions in Q2 2024.
During Q2 2024, Redmile Group, LLC's top holdings by market value included KRYS (11.3%)、AM6 (6.3%)、NRIX (5.6%). The largest single position, KRYS, represented 11.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KRYS, AM6, NRIX) accounted for 34.1% of total reported equity market value during Q2 2024.
Top Position Liquidated / Trimmed
DCPHEUR
前期市值: $83.3M
In Q2 2024, Redmile Group, LLC made 41 total portfolio adjustments, initiating 0 new buys, adding to 6 positions, trimming 21 holdings, and fully liquidating 14 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.